Literature DB >> 10536708

Adenosine plasma concentration in pulmonary hypertension.

A Y Saadjian1, F Paganelli, M L Gaubert, S Levy, R P Guieu.   

Abstract

OBJECTIVE: In this study, we sought to appreciate the role of adenosine in the regulation of pulmonary vascular tone, especially in the case of clinical pulmonary hypertension, by investigating the relationship between endogenous plasma adenosine levels and pulmonary artery vasoconstriction.
METHODS: Adenosine plasma concentrations, were measured simultaneously in the distal right pulmonary artery and in the femoral artery, both at steady state (room air) and during pure oxygen inhalation. Three clinical situations were considered: (1) normal hemodynamics [7 control subjects, mean pulmonary artery pressure (MPAP) = 18.5 +/- 1 mm Hg], (2) moderate pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD), (8 patients, MPAP = 31 +/- 3 mm Hg), (3) severe primary pulmonary hypertension (PPH), (8 patients, MPAP = 70 +/- 5 mm Hg).
RESULTS: In every instance, adenosine evaluated by HPLC was higher in the pulmonary than in the systemic circulation. For room air, adenosine plasma concentrations were significantly lower in COPD (0.49 +/- 0.16 mumol l-1) and PPH patients (0.45 +/- 0.14 mumol l-1) than in controls (1.26 +/- 0.12 mumol l-1). During O2 administration, adenosine plasma concentrations all decreased but more so in COPD and PPH patients. The significant correlations between adenosine plasma concentrations and both pulmonary vascular resistance and PvO2, in controls, were not found in COPD or PPH patients.
CONCLUSION: The adenosine plasma concentrations in the pulmonary circulation of PPH and COPD patients are low, and may contribute to pulmonary artery hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536708     DOI: 10.1016/s0008-6363(99)00059-0

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  10 in total

1.  Absence of the adenosine A2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice.

Authors:  M H Xu; Y S Gong; M S Su; Z Y Dai; S S Dai; S Z Bao; N Li; R Y Zheng; J C He; J F Chen; X T Wang
Journal:  J Vasc Res       Date:  2010-10-08       Impact factor: 1.934

2.  Extracellular cAMP: The Past and Visiting the Future in cAMP-Enriched Extracellular Vesicles.

Authors:  Aritra Bhadra; Jenny L Hewes; April Scruggs; Chun Zhou; Ji Young Lee; Natalie Bauer
Journal:  Adv Biol (Weinh)       Date:  2021-10-28

Review 3.  CD39 in the development and progression of pulmonary arterial hypertension.

Authors:  Abbey Willcox; Natasha Ting Lee; Harshal H Nandurkar; Maithili Sashindranath
Journal:  Purinergic Signal       Date:  2022-08-10       Impact factor: 3.950

4.  Acute pulmonary embolism decreases adenosine plasma levels in anesthetized pigs.

Authors:  François Kerbaul; Youlet By; Vlad Gariboldi; Choukri Mekkaoui; Pierre Fesler; Frédéric Collart; Serge Brimioulle; Yves Jammes; Jean Ruf; Régis Guieu
Journal:  ISRN Cardiol       Date:  2011-04-26

Review 5.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

6.  Baicalin attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2A receptor-induced SDF-1/CXCR4/PI3K/AKT signaling.

Authors:  Xiaoying Huang; Peiliang Wu; Feifei Huang; Min Xu; Mayun Chen; Kate Huang; Guo-Ping Li; Manhuan Xu; Dan Yao; Liangxing Wang
Journal:  J Biomed Sci       Date:  2017-08-03       Impact factor: 8.410

7.  Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension.

Authors:  Tinne C J Mertens; Ankit Hanmandlu; Ly Tu; Carole Phan; Scott D Collum; Ning-Yuan Chen; Tingting Weng; Jonathan Davies; Chen Liu; Holger K Eltzschig; Soma S K Jyothula; Keshava Rajagopal; Yang Xia; Ashrith Guha; Brian A Bruckner; Michael R Blackburn; Christophe Guignabert; Harry Karmouty-Quintana
Journal:  Front Physiol       Date:  2018-06-01       Impact factor: 4.566

Review 8.  Adenosine and the Cardiovascular System: The Good and the Bad.

Authors:  Régis Guieu; Jean-Claude Deharo; Baptiste Maille; Lia Crotti; Ermino Torresani; Michele Brignole; Gianfranco Parati
Journal:  J Clin Med       Date:  2020-05-06       Impact factor: 4.241

9.  Adenosine protects against suicidal erythrocyte death.

Authors:  Olivier M Niemoeller; Peter J Bentzen; Elisabeth Lang; Florian Lang
Journal:  Pflugers Arch       Date:  2007-02-07       Impact factor: 4.458

10.  Purinergic Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Zongye Cai; Ly Tu; Christophe Guignabert; Daphne Merkus; Zhichao Zhou
Journal:  J Am Heart Assoc       Date:  2020-09-01       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.